Cargando…
Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury
Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings. Thus, it is important to identify biomarkers for early predictio...
Autores principales: | Kim, Seung-Hyun, Naisbitt, Dean J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695405/ https://www.ncbi.nlm.nih.gov/pubmed/26540496 http://dx.doi.org/10.4168/aair.2016.8.1.3 |
Ejemplares similares
-
Immune mechanisms of idiosyncratic drug-induced liver injury
por: Mak, Alastair, et al.
Publicado: (2017) -
Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges
por: Jee, Alison, et al.
Publicado: (2021) -
Idiosyncratic drug‐induced liver injury: A short review
por: Yamashita, Yo‐ichi, et al.
Publicado: (2017) -
Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury
por: Krueger, Winfried, et al.
Publicado: (2014) -
Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM
por: Andújar-Vera, Francisco, et al.
Publicado: (2023)